«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2017 18

Page:

2904-2907

Research Field:

Publishing date:

Info

Title:

Clinical observation of paclitaxel liposome combined with carboplatin for advanced lung adenocarcinoma patients after the treatment failure of pemetrexed combined with cisplatin

Author(s):

Li Xuan¹; Kou Lulu²; Liu Haixia²; Liu Shenlin¹

1.Affiliated Hospital of Nanjing University of Traditional Chinese Medicine，Jiangsu Nanjing 210029，China;2.Nanjing University of Chinese Medicine，Jiangsu Nanjing 210023，China.

Keywords:

lung adenocarcinoma; paclitaxel liposome; pemetrexed; carboplatin

PACS:

R734.2

DOI:

10.3969/j.issn.1672-4992.2017.18.012

Abstract:

Objective:To investigate efficacy and feasibility of paclitaxel liposome combined with carboplatin for advanced lung adenocarcinoma patients after the treatment failure of pemetrexed and cisplatin．Methods：From January 2012 to April 2015,22 patients with advanced lung adenocarcinoma were enrolled in this study．Paclitaxel liposome was given at a dose 175 mg/m2 intravenous drip,d1，with carboplatin AUC 5 intravenous drip,d1．21 days was a cycle．The efficacy and side effects were evaluated after at least two cycles of chemotherapy．Results：Therapeutic efficacy and adverse reaction could be evaluated in all patients with no CR patient，10 cases of PR，8 cases of SD and 4 cases of PD．The response rate was 45.5%，and the disease control rate was 81.8%．The median progression-free survival and the median overall survival time was 5.6 months and 9.5 months respectively．One-year survival rate was 36.4%.The main side effect was myelosuppression，which was alleviated by symptomatic treatment．Conclusion：Paclitaxel liposome combined with carboplatin for advanced lung adenocarcinoma patients after the treatment failure of pemetrexed combined with cisplatin was effective and well tolerated．

References:

［1］Wu Yungaowa,Li Wenxin,Bao Jiaqi,et al.Clinical effect of maintenance chemotherapy by pemetrexed in advanced non-small-cell lung cancer（NSCLC）［J］.Modern Oncology,2013,21(8):1766-1769.［乌云高娃,李文新,包佳琪,等.培美曲塞维持治疗晚期非小细胞肺癌的临床研究［J］.现代肿瘤医学,2013,21(8):1766-1769.］
［2］Chen W,Zheng R,Zhang S,et al.Annual report onstatus of cancer in China,2010［J］.Chin J Cancer Res,2014,26(1):48-58.
［3］Scheff RJ,Schneider BJ.Non-small-cell lung cancer:treatment of late stage disease:chemotherapeutics and new frontiers［J］.Semin In-tervent Radiol,2013,30(2):191-198．
［4］Scagliotti GV,Parikh P,von Pawel J,et al．Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small-cell lung cancer［J］.J Clin Oncol,2008,26(21):3543-3551.
［5］Zhao Min,Zhang Hongbin,Liang Jian,et al.Comparison of paclitaxel liposome and paclitaxel plus cisplatin in patients with non-small cell lung cancer［J］.Chin Clin Oncol,2010,15(4):343-345.［赵敏,张红斌,梁健，等.紫杉醇脂质体与紫杉醇联合顺铂治疗晚期非小细胞肺癌对比研究［J］.临床肿瘤学杂志,2010,15(4):343-345.］
［6］Li Xiaohong.Efficacy and adverse reactions of paclitaxel drugs in neoadjuvant chemotherapy of the elderly patients with breast cancer［J］.Journal of Clinical Medicine in Practice,2013,17(15):74-76.［李晓红.紫杉醇类药物用于老年乳腺癌患者新辅助化疗及不良反应分析［J］.实用临床医药杂志,2013,17(15):74-76.］
［7］Wang Hongyu,Zhang Xiangru.Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in acvanced non-small cell lung cancer［J］.Acta Academiae Medicinae Sinicae,2014,36(3):305-308.［王宏羽，张湘茹.脂质体紫杉醇联合卡铂与紫杉醇联合卡铂一线治疗晚期非小细胞肺癌的疗效和安全性的比较［J］.中国医学科学院学报,2014,36(3):305-308.］
［8］Cheng G,Chen WZ,Cheng XW,et al.The application of liposome technology in the research and development of anti-tumor drugs［J］.Shanghai Medical and Pharmaceutical Journal,2010,31(11):489-491.
［9］Qian J,Wang YX,Yu YQ,et al.A comparison of pharmacokinetics between paclitaxel liposome for injection and commercial paclitaxel injection in patients with cancer ［J］.Tumor,2011,31(12):1103-1107.［钱隽,王漪璇,郁韵秋,等.注射用紫杉醇脂质体与紫杉醇注射液在肿瘤患者中的药动学比较［J］.肿瘤,2011,31(12):1103-1107.］
［10］Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung Cancer ［J］.N Engl J Med,2002,346(2):92-96.
［11］Qian L,Miao JF,Mao GX.The efficacy and safety of weekly paclitaxel liposome combined with carboplatin in elderly patients with advanced non-small cell lung cancer ［J］.Rehabilitation and Clinical Oncology of China,2013,20(7):741-743.［钱俐,繆捷飞,茅国新.紫杉醇脂质体联合卡铂治疗老年晚期非小细胞肺癌的疗效观察［J］.中国肿瘤临床与康复,2013,20(7):741-743.］
［12］Minegishi Y,Sudoh J,Kuribayasi H,et al.The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias［J］.Lung Cancer,2011,71:70-74.

Memo

Memo:

-

Common functions

Last Update: 1900-01-01